Octreotide Reduces Malignant Potential of Glioblastoma Multiforme to the Level of Low Grade Astrocytomas - Clinical Study

摘要

Surgical and oncological treatment are insufficient in curing glioblastoma multiforme of brain (GM).We have researched clinical effects of applying Octreotide in patients operated of supratentorial GM. The study included 60 patients of both sexes, of different ages, who were treated oncologicaly. One half was subcutaneously receiving 200 fig of Octreotide, immediately after the operation, 3 times a day, during 3 weeks. The patients were monitored for more than 3 years. In the group treated by Octreotide enlengthened time of recidiving (R_(50)) from 7 to 18 months, and survival time (L_(50)) from 11 to 24 months, importantly lower level of cell pleomorphism, pathological mitosis, intra and extra cellular edemas, supremated neovascularisation and less endoplasmatic vesicles were indicated. Octreotide reduces the malignant potential of GM to the level of low - grade astrocytomas.